Breast cancer, especially the hormone receptor-positive variants, remains a prominent cause of illness and death globally. Tamoxifen, a commonly utilized treatment, has markedly enhanced outcomes for numerous patients; however, its efficacy is not consistent across all cases, and the issue of resistance poses a significant obstacle. This research investigates the molecular mechanisms that influence the response to tamoxifen by examining gene expression profiles in both treated and untreated samples. By pinpointing critical genes that exhibit notable differences in expression between these groups, we reveal potential biomarkers that could forecast patient responses and resistance. This analysis not only underscores the intricate nature of drug responses at the molecular level but also highlights the necessity for personalized treatment approaches. The results offer important insights into the transcriptional changes triggered by tamoxifen, establishing a foundation for future studies focused on therapeutic targeting and the mechanisms of drug resistance in breast cancer.